T-E Pharma Holding

T-E Pharma Holding is a clinical-stage biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) and targeted therapies. The company leverages its proprietary T-E Linker platform, which enables site-specific conjugation to produce homogeneous drug products with enhanced stability and a wider therapeutic index. Its lead program, TE-1146, is a HER2-targeted ADC currently undergoing Phase 1 clinical trials for patients with advanced solid tumors. T-E Pharma aims to redefine cancer treatment by optimizing the delivery of potent cytotoxic payloads through innovative chemical engineering and site-specific conjugation technologies. The company operates primarily through its subsidiary, T-E Meds, based in Taiwan.